Editor’s Summary: Glucagon-like peptide-1 (GLP-1)-based therapies have revolutionized type 2 diabetes treatment through GLP-1 receptor agonists and dipeptidyl peptidase-4 (DPP-4) inhibitors. Read about how these therapies enhance insulin secretion, inhibit glucagon, and offer benefits like weight loss and cardiovascular protection. Clinical trials show significant HbA1c reductions and improved safety profiles. Despite challenges, GLP-1-based treatments are crucial in diabetes management, combining efficacy with minimal side effects.

GLP-1-Based Therapy in Type 2 Diabetes: Mechanisms, Efficacy, and Clinical Applications

Abstract

Glucagon-like peptide-1 (GLP-1)-based therapy has emerged as a novel and effective approach for the treatment of type 2 diabetes. This therapy is implemented either through GLP-1 receptor agonists or dipeptidyl peptidase-4 (DPP-4) inhibitors. This paper reviews the mechanisms of action, efficacy, and clinical applications of GLP-1-based therapies in type 2 diabetes management. Clinical trials have demonstrated significant reductions in HbA1c levels, with additional benefits including potential beta cell preservation, body weight reduction, and cardio-endothelioprotective effects. The safety profile and efficacy in combination with other antidiabetic medications make GLP-1-based therapies a valuable addition to the treatment arsenal for type 2 diabetes.

1. Introduction

Type 2 diabetes is a complex metabolic disorder characterized by hyperglycemia resulting from insulin resistance and/or impaired insulin secretion. The management of this condition has evolved significantly over the past few decades, with the introduction of novel therapies targeting various aspects of glucose homeostasis. Among these, glucagon-like peptide-1 (GLP-1)-based therapies have gained considerable attention due to their unique mechanism of action and multifaceted benefits.

The incretin effect, first described in the 1960s, refers to the phenomenon where oral glucose administration elicits a larger insulin secretion than intravenous glucose when glucose levels are matched. This effect is attributed to gut incretin hormones, primarily glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) [1]. GLP-1, a 30 amino acid peptide produced by intestinal L-cells in response to meal ingestion, has become a focal point in diabetes research due to its potent insulinotropic and glucoregulatory properties.

This paper aims to provide a comprehensive overview of GLP-1-based therapies in the context of type 2 diabetes management. We will explore the physiological actions of GLP-1, the development of GLP-1-based therapeutic approaches, their mechanisms of action, clinical efficacy, and potential extrapancreatic effects.

2. Physiological Actions of GLP-1

2.1 Pancreatic Effects

GLP-1 exerts its effects through binding to the GLP-1 receptor, a G protein-coupled receptor expressed in various tissues, including pancreatic beta cells. The activation of this receptor leads to increased cyclic AMP (cAMP) levels, which in turn activates protein kinase A and Epac 1 and 2, resulting in enhanced glucose-dependent insulin secretion [2].

In addition to its insulinotropic effects, GLP-1 has been shown to increase beta cell mass in rodent studies. This is achieved through stimulation of beta cell neogenesis and proliferation, coupled with inhibition of apoptosis [3]. Furthermore, GLP-1 inhibits glucagon secretion from pancreatic alpha cells, an effect that is also glucose-dependent [4].

2.2 Extrapancreatic Effects

GLP-1 has several extrapancreatic effects that contribute to its therapeutic potential in type 2 diabetes:

1. Inhibition of gastric emptying [5]
2. Induction of satiety and reduction in food intake [6]
3. Potential cardio- and endothelioprotective effects

These diverse actions of GLP-1 make it an attractive target for diabetes therapy, addressing multiple aspects of the disease pathophysiology.

3. Development of GLP-1-Based Therapies

The potential of GLP-1 as a therapeutic target for type 2 diabetes was first recognized in the early 1990s. A seminal study demonstrated that intravenous infusion of GLP-1 in subjects with diabetes reduced the insulin requirement for meal ingestion [7]. Subsequent research, including a study showing improved glycemic control and body weight reduction after six weeks of continuous subcutaneous GLP-1 infusion in type 2 diabetes patients [8], further solidified the therapeutic potential of GLP-1.

However, the development of GLP-1-based therapies faced a significant challenge: the active form of GLP-1 has a very short half-life of only 1-2 minutes due to rapid inactivation by the enzyme dipeptidyl peptidase-4 (DPP-4) [1]. To overcome this limitation, two main strategies have been developed:

1. GLP-1 receptor agonists: These are modified GLP-1 molecules that are resistant to DPP-4 degradation.
2. DPP-4 inhibitors: These drugs inhibit the DPP-4 enzyme, thereby prolonging the action of endogenous GLP-1.

Both approaches have been successfully translated into clinical practice and are now established treatments for type 2 diabetes worldwide [9].

4. Clinical Efficacy of GLP-1-Based Therapies

Clinical trials have demonstrated the efficacy of GLP-1-based therapies in improving glycemic control in type 2 diabetes patients. In studies lasting 12 weeks or more, these treatments have been shown to reduce HbA1c by approximately 0.8-1.1% from baseline levels of 7.7-8.5%.

These therapies have proven effective both as monotherapy and in combination with other antidiabetic medications, including metformin, sulfonylureas, thiazolidinediones, and insulin. The combination of GLP-1-based therapy with metformin has shown particular promise in patients inadequately controlled by metformin alone.

An important distinction between the two types of GLP-1-based therapies is their effect on body weight. GLP-1 receptor agonists have been shown to reduce body weight, while DPP-4 inhibitors are generally weight-neutral.

5. Safety Profile

GLP-1-based therapies have demonstrated a favorable safety profile in clinical trials. The risk of adverse events, including hypoglycemia, is very low. This safety profile, combined with their efficacy, makes GLP-1-based therapies an attractive option for many patients with type 2 diabetes.

6. Conclusion

GLP-1-based therapies represent a significant advancement in the treatment of type 2 diabetes. By leveraging the multifaceted actions of GLP-1, these therapies offer improvements in glycemic control, potential beta cell preservation, and in the case of GLP-1 receptor agonists, body weight reduction. Their efficacy in combination with other antidiabetic medications and favorable safety profile make them a valuable addition to the diabetes treatment armamentarium.

Future research should focus on long-term outcomes, potential cardioprotective effects, and the role of these therapies in diabetes prevention. As our understanding of GLP-1 biology continues to expand, we may uncover additional therapeutic applications for these innovative treatments.

References

1. Holst JJ. The physiology of glucagon-like peptide 1. Physiol Rev. 2007;87(4):1409-1439.
2. Drucker DJ. The biology of incretin hormones. Cell Metab. 2006;3(3):153-165.
3. Xu G, Stoffers DA, Habener JF, Bonner-Weir S. Exendin-4 stimulates both beta-cell replication and neogenesis, resulting in increased beta-cell mass and improved glucose tolerance in diabetic rats. Diabetes. 1999;48(12):2270-2276.
4. Strain WD, Paldánius PM. GLP-1 receptor agonists: practical tips for primary care. https://www.diabetestherapy-online.com/content/1/1/14. Accessed July 17, 2024.
5. Nauck MA, Kleine N, Orskov C, Holst JJ, Willms B, Creutzfeldt W. Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients. Diabetologia. 1993;36(8):741-744.
6. Wettergren A, Schjoldager B, Mortensen PE, Myhre J, Christiansen J, Holst JJ. Truncated GLP-1 (proglucagon 78-107-amide) inhibits gastric and pancreatic functions in man. Dig Dis Sci. 1993;38(4):665-673.
7. Flint A, Raben A, Astrup A, Holst JJ. Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans. J Clin Invest. 1998;101(3):515-520.
8. Gutniak M, Orskov C, Holst JJ, Ahrén B, Efendic S. Antidiabetogenic effect of glucagon-like peptide-1 (7-36)amide in normal subjects and patients with diabetes mellitus. N Engl J Med. 1992;326(20):1316-1322.
9. Zander M, Madsbad S, Madsen JL, Holst JJ. Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study. Lancet. 2002;359(9309):824-830.
10. Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet. 2006;368(9548):1696-1705.